STAT+: OHSU board votes to negotiate with NIH and transfo...

What’s Happening

Listen up: The vote came as NIH looks to transition at least one of seven national primate research centers into an animal sanctuary.

Pharmalot Pharmalot STAT Plus: FDA warned a Hims & Hers compounder after finding bugs and failing to report a serious side effect By Ed Silverman Pharmalot Pharmalot STAT Plus: Pharmalittle: Were reading about Novo Nordisk suing Hims & Hers, deals Takeda, and more By Ed Silverman Pharmalot Pharmalot STAT Plus: Lawsuit against Hims & Hers should be ‘wake-up call’ for compounders, Novo chief counsel says By Elaine Chen and Ed Silverman Pharmalot Pharmalot STAT Plus: Novo Nordisk sues Hims & Hers for infringing on a key Wegovy patent By Ed Silverman Pharmalot Pharmalot STAT Plus: HHS asks Justice Department to probe Hims & Hers over its cheaper compounded version of Wegovy By Ed Silverman STAT Plus: Vertex’s CRISPR treatment for sickle cell disease hits unexpected roadblock By Jason Mast STAT Plus: A rival goes after Ocular Therapeutix on eve of pivotal readout on eye treatment By Adam Feuerstein STAT Plus: Nektar Therapeutics is trying to stage a comeback. (wild, right?)

Why This Matters

Medical professionals are taking note of this development.

Health experts are weighing in on what this means for people.

The Bottom Line

This story is still developing, and we’ll keep you updated as more info drops.

Is this a W or an L? You decide.